Table 1 Odds ratios related to polymorphisms linked to resistance, according to the drug and the duration of the follow-up. Genotyping (gen.) means that analyse was limited to studies that discriminate between reinfection and recrudescence.
Gene | Polymorphism | Drug | Follow-up (genotyping) | Odds Ratio | Confidence intervals 95% | Nb of studies |
|---|---|---|---|---|---|---|
Pfmdr | N86Y | Chloroquine | 14 | 2.2 | 1.6 – 3.1 | 11 |
|  | - | - | 28–42 | 1.8 | 1.3 – 2.4 | 11 |
|  | - | - | 28 (gen.) | 1.9 | 1.3 – 2.7 | 7 |
|  | - | Amodiaquine | 14–21–28 | 5.4 | 2.6 – 11.2 | 6 |
Pfmdr | Copy number | Mefloquine | 28 | 8.6 | 3.3 – 22.9 | 1 |
|  | - | Mefloquine + artesunate | 42 | 2.6 | 1.2 – 5.6 | 1 |
Pfcrt | K76T | Chloroquine | 14 | 2.1 | 1.5 – 3.0 | 13 |
|  | - | - | 28 | 7.2 | 4.5 – 11.5 | 12 |
|  | - | - | 28 (gen.) | 5.1 | 3.1 – 8.45 | 8 |
Pfmdr + Pfcrt | N86Y + K76T | Chloroquine | 14–28 | 3.9 | 2.6 – 5.8 | 5 |
Pfdhfr | 108 | Sulphadoxine-pyrimethamine | 14–28 | 2.1 | 1.4 – 3.0 | 18 |
|  | 108 | - | 28 | 3.5 | 1.9 – 6.3 | 10 |
|  | 51 | - | 14–28 | 1.7 | 1.0 – 3.0 | 6 |
|  | 59 | - | 14–28 | 1.9 | 1.4 – 2.6 | 13 |
|  | 51+59+108 | - | 14–28 | 4.3 | 3.0 – 6.3 | 16 |
|  | 51+59+108 | - | 28 (gen.) | 3.1 | 2.0 – 4.9 | 8 |
Pfdhps | 437 | Sulphadoxine-pyrimethamine | 14–28 | 1.5 | 1.0 – 2.4 | 12 |
|  | 437 + 540 | - | 14–28 | 3.9 | 2.6 – 5.8 | 10 |
Pfdhfr + Pfdhps | Quintuple | Sulphadoxine-pyrimethamine | 14–28 | 5.2 | 3.2 – 8.8 | 3 |